PET-CT scans can better predict long-term benefit of checkpoint inhibitor treatment than CT and also help guide discontinuation of therapy, an Australian study in patients with malignant melanoma has shown. The increasing use of anti-PD-1 based immune checkpoint inhibitor therapy has resulted in good clinical outcomes for patients with many kinds of cancers including those ...
PET a better guide for anti-PD-1 outcomes and discontinuation
By Michael Woodhead
29 Aug 2018